Difference between revisions of "Lenalidomide (Revlimid)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:POEMS" to "Category:POEMS syndrome")
Line 42: Line 42:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*12/28/2005: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108546.htm FDA approved] for patients with "transfusion-dependent anemia due to [[Myelodysplastic syndrome | low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities]]."<ref name="insert"></ref>
+
===[[Follicular lymphoma]]; [[Marginal zone lymphoma]]===
−
*6/29/2006: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm FDA approved] for treatment of patients with "[[Multiple myeloma |multiple myeloma (MM)]], in combination with [[Dexamethasone (Decadron) | dexamethasone]], in patients who have received at least one prior therapy.]<ref name="insert"></ref>
+
*5/28/2019: Approved in combination with a rituximab product for previously treated [[Follicular lymphoma|follicular lymphoma (FL)]] and previously treated [[marginal zone lymphoma|marginal zone lymphoma (MZL)]]. ''(New disease entity)''
−
*6/5/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm FDA approved] for patients with "[[Mantle cell lymphoma |mantle cell lymphoma (MCL)]] whose disease has relapsed or progressed after two prior therapies, one of which included [[Bortezomib (Velcade) | bortezomib]]."<ref name="insert"></ref>
+
 
−
*2/22/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm FDA approval expanded] "as maintenance therapy for patients with [[multiple myeloma]] following autologous stem cell transplant."
+
===[[Mantle cell lymphoma]]===
 +
*6/5/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm Approved] for patients with [[Mantle cell lymphoma |mantle cell lymphoma (MCL)]] whose disease has relapsed or progressed after two prior therapies, one of which included [[Bortezomib (Velcade) | bortezomib]].<ref name="insert"></ref> ''(New disease entity)''
 +
 
 +
===[[Myelodysplastic syndrome]]===
 +
*12/28/2005: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108546.htm Approved] for patients with transfusion-dependent anemia due to [[Myelodysplastic syndrome | low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities]].<ref name="insert"></ref> ''(Initial approval)''
 +
 
 +
===[[Multiple myeloma]]===
 +
*6/29/2006: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm Approved] for treatment of patients with "[[Multiple myeloma |multiple myeloma (MM)]], in combination with [[Dexamethasone (Decadron) | dexamethasone]], in patients who have received at least one prior therapy.]<ref name="insert"></ref> ''(New disease entity)''
 +
*2/22/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm Approval expanded] as maintenance therapy for patients with [[multiple myeloma]] following autologous stem cell transplant. ''(Approval expanded to maintenance therapy after upfront treatment)''
  
 
==Also known as==
 
==Also known as==

Revision as of 17:33, 29 May 2019

General information

Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to Thalidomide (Thalomid); mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.[1][2][3][4]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Significant side effects

Thrombosis

  • 2006 (two simultaneously published NEJM letters to the editor): link to original article PubMed link to letter #1 PubMed link to letter #2
  • 2011: Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012 Jan 26;119(4):933-9. Epub 2011 Aug 11. link to original article PubMed

Patient drug information

History of changes in FDA indication

Follicular lymphoma; Marginal zone lymphoma

Mantle cell lymphoma

Myelodysplastic syndrome

Multiple myeloma

Also known as

  • Code names: CC-5013, IMiD-1, NSC-703813
  • Brand names: Kabillon, Lenalid, Lenangio, Lenmid, Lenome, Lenzest, MyeloSar, Revlimid

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Lenalidomide (Revlimid) package insert
  2. ↑ Lenalidomide (Revlimid) package insert (locally hosted backup)
  3. ↑ Revlimid manufacturer's site
  4. ↑ 4.0 4.1 Revlimid REMS program
  5. ↑ Lenalidomide (Revlimid) patient medication guide
  6. ↑ Lenalidomide (Revlimid) patient drug information (Chemocare)
  7. ↑ Lenalidomide (Revlimid) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Lenalidomide_(Revlimid)&oldid=37719"